natgillin/translations-raw huggingface dataset:
Because of individual variability, titration to optimal therapeutic doses is expected for individual patients.
Zaradi individualne variabilnosti je pričakovati, da bo pri posameznem bolniku potrebno prilagajanje do optimalnega terapevtskega odmerka.
Because of individual variability, titration to optimal therapeutic doses is expected for individual patients.
Zaradi individualne variabilnosti je treba pričakovati, da bo pri posameznem bolniku potrebno prilagajanje do optimalnega terapevtskega odmerka.
Because of its deep red color, hydroxocobalamin may cause haemodialysis machines to shut down due to an erroneous detection of a ‘blood leak’.
Zaradi svoje temno rdeče barve lahko hidroksokobalamin povzroči, da se aparature za hemodializo izklopijo zaradi napačne zaznave „iztekanja krvi“.
Because of its potential anticholinergic properties, Clomicalm should also be used with care in dogs with narrow angle glaucoma, reduced gastrointestinal motility or urinary retention.
Zaradi njegovih potencilanih antiholinergičnih lastnosti je potrebna previdnost pri uporabi pri psih, ki imajo glaukom, zmanjšano gastrointestinalno aktivnost ali urinarno retencijo.
Because of its potential for inducing orthostatic hypotension (see section 4.4), an additive effect may be observed when TREVICTA is administered with other therapeutic agents that have this potential, e.g., other antipsychotics, tricyclics.
Zdravilo TREVICTA lahko povzroči ortostatsko hipotenzijo (glejte poglavje 4.4), zato je pri sočasni uporabi zdravila TREVICTA in drugih zdravil z enakim delovanjem, kot so drugi antipsihotiki in triciklični antidepresivi, mogoče opaziti aditivni učinek.
Because of its potential for inducing orthostatic hypotension (see section 4.4), an additive effect may be observed when Xeplion is administered with other therapeutic agents that have this potential, e.g., other antipsychotics, tricyclics.
Zdravilo Xeplion lahko povzroči ortostatsko hipotenzijo (glejte poglavje 4.4), zato lahko pri sočasni uporabi zdravila Xeplion in drugih zdravil z enakim delovanjem, npr. drugi antipsihotiki, triciklični antidepresivi, opazimo aditivni učinek.
Because of its similarities to the smallpox virus, the antibodies produced against this virus are also expected to protect against smallpox.
Ker ima podobne lastnosti kot virus črnih koz, naj bi protitelesa, ki se tvorijo proti njemu, ščitila tudi pred virusom črnih koz.
Because of its α1-adrenergic antagonism with potential for inducing orthostatic hypotension (see section 4.4), Sycrest may enhance the effects of certain antihypertensive agents.
Zaradi antagonističnega delovanja zdravila Sycrest na adrenergične receptorje α1 z možnostjo, da bo povzročilo ortostatsko hipotenzijo (glejte poglavje 4.4), lahko to zdravilo okrepi učinke določenih antihipertenzivov.
Because of known increased risks of bleeding in conjunction with the use of imatinib (e.g. haemorrhage), patients who require anticoagulation should receive low-molecular-weight or standard heparin, instead of coumarin derivatives such as warfarin.
Zaradi znanega zvečanega tveganja krvavitev ob uporabi imatiniba (n.pr. hemoragij) naj bolniki, pri katerih je potrebna antikoagulantna terapija, namesto kumarinskih derivatov, n.pr. varfarina, dobivajo nizkomolekularni ali standardni heparin.
Because of lack of experience, Victoza should not be used during breast­feeding.
Zaradi pomanjkanja izkušenj se zdravila Victoza ne sme uporabljati med dojenjem.
Because of limited information on safety and effectiveness in infants below four months of age, Emtriva is not recommended for use in this age group.
Zaradi omejenih podatkov o varnosti in učinkovitosti pri otrocih, mlajših od štirih let, uporaba zdravila Emtriva v tej starostni skupini ni priporočljiva.
Because of possible additive effects, caution should be advised when patients are taking other sedating medication or alcohol in combination with pramipexole (see sections 4.5, 4.7 and section 4.8).
Zaradi možnih aditivnih učinkov je treba bolnikom svetovati, naj bodo previdni, če hkrati s pramipeksolom jemljejo še druga zdravila s sedativnim učinkom ali če pijejo alkoholne pijače (glejte poglavja 4.5, 4.7 in 4.8).
Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole (see section 4.4, 4.7 and 4.8).
Zaradi možnih aditivnih učinkov svetujemo bolnikom previdnost pri jemanju drugih sedativnih zdravil ali alkohola v kombinaciji s pramipeksolom (glejte poglavja 4.4, 4.7 in 4.8).
Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole (see section 4.4, 4.7 and 4.8).
Zaradi možnosti seštevanja učinka morajo biti bolniki previdni, če jemljejo druga sedativna zdravila ali uživajo alkohol sočasno s pramipeksolom.
Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole.
Bolnikom, ki jemljejo pramipeksol, zaradi možnih aditivnih učinkov svetujemo previdnost pri jemanju drugih sedativnih zdravil in pri sočasnem pitju alkoholnih pijač.
Because of possible excretion in human milk and because of the potential for serious adverse reactions in nursing infants, the use of DepoCyte is not recommended in breast-feeding women.
Zaradi možnosti izločanja v materinem mleku in morebitnih resnih neželenih reakcij za dojene dojenčke se uporaba zdravila DepoCyte doječim ženskam odsvetuje.
Because of potential effects on spermatogenesis associated with radiation, men should be advised to use effective contraceptive methods during and up to 6 months after treatment with Xofigo.
Zaradi možnih učinkov na spermatogenezo, povezanih s sevanjem, je treba moškim svetovati, da med zdravljenjem in do 6 mesecev po zdravljenju z zdravilom Xofigo uporabljajo učinkovite metode kontracepcije.
Because of the genotoxic and teratogenic potential of CellCept, women with childbearing potential should use two reliable forms of contraception simultaneously before beginning CellCept therapy, during therapy, and for six weeks following discontinuation of therapy; unless abstinence is the chosen method of contraception (see section 4.5).
Zaradi genotoksičnega in teratogenega potenciala zdravila CellCept morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom CellCept hkrati uporabljati dve zanesljivi obliki kontracepcije, če niso izbrale metode vzdržnosti (glejte poglavje 4.5).
Because of the genotoxic and teratogenic potential of CellCept, women with childbearing potential should use two reliable forms of contraception simultaneously before starting CellCept therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception (see section 4.5).
Zaradi genotoksičnega in teratogenega potenciala zdravila CellCept morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom CellCept hkrati uporabljati dve zanesljivi obliki kontracepcije, razen če niso izbrale metode vzdržnosti (glejte poglavje 4.5).
Because of the genotoxic and teratogenic potential of CellCept, women with childbearing potential should use two reliable forms of contraception simultaneously before starting CellCept therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception (see section 4.5).
Zaradi genotoksičnega in teratogenega potenciala zdravila CellCept morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom CellCept hkrati uporabljati dve zanesljivi obliki kontracepcije, če niso izbrale metode vzdržnosti (glejte poglavje 4.5).
Because of the genotoxic and teratogenic potential of CellCept, women with childbearing potential should use two reliable forms of contraception simultaneously before starting CellCept therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception (see section 4.5).
Zaradi genotoksičnega in teratogenega potenciala zdravila CellCept morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem ter šest tednov po končanem zdravljenju z zdravilom CellCept hkrati uporabljati dve zanesljivi obliki kontracepcije, če niso izbrale metode vzdržnosti (glejte poglavje 4.5).
Because of the genotoxic and teratogenic potential of mycophenolate mofetil women with childbearing potential should use two reliable forms of contraception simultaneously before starting Myclausen therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception (see section 4.5).
Zaradi genotoksičnega in teratogenega potenciala zdravila Myclausen morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom Myclausen hkrati uporabljati dve zanesljivi obliki kontracepcije, če niso izbrale metode vzdržnosti (glejte poglavje 4.5).
Because of the genotoxic and teratogenic potential of mycophenolate mofetil women with childbearing potential should use two reliable forms of contraception simultaneously before starting Myclausen therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception (see section 4.5).
Zaradi genotoksičnega in teratogenega potenciala zdravila Myclausen morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem ter šest tednov po končanem zdravljenju z zdravilom Myclausen hkrati uporabljati dve zanesljivi obliki kontracepcije, če niso izbrale metode vzdržnosti (glejte poglavje 4.5).
Because of the genotoxic and teratogenic potential of mycophenolate mofetil, women with childbearing potential should use two reliable forms of contraception simultaneously before starting Myclausen therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception (see section 4.5).
Zaradi genotoksičnega in teratogenega potenciala zdravila Myclausen morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom Myclausen hkrati uporabljati dve zanesljivi obliki kontracepcije, razen če niso izbrale metode vzdržnosti (glejte poglavje 4.5).
Because of the genotoxic and teratogenic potential of mycophenolate, women with childbearing potential should use two reliable forms of contraception simultaneously before starting Mycophenolate mofetil Teva therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception (see section 4.5).
Zaradi genotoksičnega in teratogenega potenciala mofetilmikofenolata morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom Mofetilmikofenolat Teva hkrati uporabljati dve zanesljivi obliki kontracepcije, razen če niso izbrale metode vzdržnosti (glejte poglavje 4.5).
Because of the genotoxic and teratogenic potential of mycophenolate, women with childbearing potential should use two reliable forms of contraception simultaneously before starting Mycophenolate mofetil Teva therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception (see section 4.5).
Zaradi genotoksičnega in teratogenega potenciala mofetilmikofenolata morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom Mofetilmikofenolat Teva hkrati uporabljati dve zanesljivi obliki kontracepcije, če niso izbrale metode vzdržnosti (glejte poglavje 4.5).
Because of the genotoxic and teratogenic potential of mycophenolate, women with childbearing potential should use two reliable forms of contraception simultaneously before starting Myfenax therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception (see section 4.5).
Zaradi genotoksičnega in teratogenega potenciala mofetilmikofenolata morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom Myfenax hkrati uporabljati dve zanesljivi obliki kontracepcije, razen če niso izbrale metode vzdržnosti (glejte poglavje 4.5).
Because of the genotoxic and teratogenic potential of mycophenolate, women with childbearing potential should use two reliable forms of contraception simultaneously before starting Myfenax therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception (see section 4.5).
Zaradi genotoksičnega in teratogenega potenciala mofetilmikofenolata morajo bolnice v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom Myfenax hkrati uporabljati dve zanesljivi obliki kontracepcije, če niso izbrale metode vzdržnosti (glejte poglavje 4.5).
Because of the higher risk of diarrhoea seen in the clinical trials (see section 4.8), special attention should be given to these patients and the treatment benefit- risk ratio should be carefully and periodically assessed.
Zaradi visokega tveganja za pojav driske, ki so ga opazili pri kliničnih preskušanjih (glejte poglavje 4.8), je treba tem bolnikom posvetiti posebno pozornost, skrbno in redno pa je treba ocenjevati tudi razmerje med koristmi in tveganji zdravljenja.
Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking lenalidomide in combination therapy, and to a lesser extent in patients with mantle cell lymphoma taking lenalidomide monotherapy, combined oral contraceptive pills are not recommended (see also section 4.5).
Zaradi povečanega tveganja za vensko trombembolijo pri bolnicah z diseminiranim plazmocitomom, ki jemljejo lenalidomid v okviru kombiniranega zdravljenja, in v manjšem obsegu pri bolnicah z limfomom plaščnih celic, ki jemljejo monoterapijo z lenalidomidom, uporaba kombiniranih peroralnih kontracepcijskih tablet ni priporočena (glejte tudi poglavje 4.5).
Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking lenalidomide in combination therapy, and to a lesser extent in patients with myelodysplastic syndromes and mantle cell lymphoma taking lenalidomide monotherapy, combined oral contraceptive pills are not recommended (see also section 4.5).
Zaradi povečanega tveganja za vensko trombembolijo pri bolnicah z diseminiranim plazmocitomom, ki jemljejo lenalidomid v okviru kombiniranega zdravljenja, in v manjšem obsegu pri bolnicah z mielodisplastičnimi sindromi in limfomom plaščnih celic, ki se zdravijo z monoterapijo z lenalidomidom, uporaba kombiniranih peroralnih kontracepcijskih tablet ni priporočena (glejte tudi poglavje 4.5).
Because of the increased risk of venous thromboembolism in patients with multiple myeloma, combined oral contraceptive pills are not recommended (see section 4.5).
Zaradi povečanega tveganja za vensko trombembolijo pri bolnicah z diseminiranim plazmocitomom uporaba kombiniranih peroralnih kontracepcijskih tablet ni priporočljiva (glejte poglavje 4.5).
Because of the nature of the adverse events seen with combination of etanercept and anakinra therapy, similar toxicities may also result from the combination of anakinra and other TNFα-blocking agents.
Glede na vrsto neželenih sopojavov, ki so jih opažali pri kombinirani terapiji z etanerceptom in anakinro, lahko podobni toksični učinki nastopijo tudi kot posledica kombiniranja anakinre in drugih zaviralcev TNFα.
Because of the nature of the adverse events seen with combination of etanercept and anakinra therapy, similar toxicities may also result from the combination of anakinra and other TNF-blocking agents.
Glede na vrsto neželenih sopojavov, ki so jih opažali pri kombinirani terapiji z etanerceptom in anakinro, lahko podobni toksični učinki nastopijo tudi kot posledica kombiniranja anakinre in drugih zaviralcev TNF.
Because of the pharmacological properties of prednisolone, special care should be taken when the veterinary medicinal product is used in animals with a weakened immune system.
Zaradi farmakoloških lastnosti prednizolona je potrebna posebna previdnost, kadar se zdravilo uporablja pri živalih z oslabljenim imunskim sistemom.
Because of the possibility of infertility as a consequence of Dacogen therapy, men should seek advice on conservation of sperm and female patients of childbearing potential should seek consultation regarding oocyte cryopreservation prior to initiation of treatment with Dacogen.
Zaradi možnosti, da bi zdravljenje z zdravilom Dacogen povzročilo neplodnost, naj se moški posvetujejo glede shranjevanja sperme, ženske v rodni dobi pa glede zamrzovanja jajčec še pred začetkom zdravljenja z zdravilom Dacogen.
Because of the possibility of interactions with other medications, your doctor may change the time of day you take your medications.
Zaradi možnih interakcij z drugimi zdravili lahko zdravnik spremeni čas v dnevu, ko boste zdravilo jemali.
Because of the potential for adverse reactions in breast-fed infants from sirolimus, breast-feeding should be discontinued during treatment with Rapamune.
Zaradi možnosti pojava neželenih učinkov sirolimusa pri dojenih otrocih se priporoča, da mati med zdravljenjem z zdravilom Rapamune preneha z dojenjem.
Because of the potential for adverse reactions in breast-fed infants from temsirolimus, breast-feeding should be discontinued during therapy.
Zaradi možnosti neželenih reakcij, ki bi jih pri dojenih otrocih lahko povzročil temsirolimus, mora mati med zdravljenjem prenehati dojiti.
Because of the potential for adverse reactions in breast-fed infants, breast-feeding must be discontinued prior to initiation of treatment.
Zaradi nevarnosti za pojav neželenih učinkov pri dojenih dojenčkih je treba pred zdravljenjem prenehati z dojenjem.
Because of the potential for adverse reactions in nursing infants from pomalidomide, a decision should be made whether to discontinue nursing or to discontinue the medicinal product, taking into account the importance of the medicinal product to the mother.
Zaradi možnih neželenih učinkov pomalidomida pri dojenih otrocih se je treba odločiti med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja, pri čemer je treba upoštevati prednosti zdravljenja za mater.
Because of the potential for adverse reactions in nursing infants from secukinumab, a decision on whether to discontinue breast-feeding during treatment and up to 20 weeks after treatment or to discontinue therapy with Cosentyx must be made taking into account the benefit of breast-feeding to the child and the benefit of Cosentyx therapy to the woman.
Zaradi možnosti razvoja neželenih učinkov sekukinumaba pri dojenem otroku se je treba odločiti, ali bo bolnica prenehala z dojenjem v času zdravljenja in obdobju 20 tednov po zaključku zdravljenja ali bo prekinila zdravljenje z zdravilom Cosentyx, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja z zdravilom Cosentyx za mater.
Because of the potential for increased risk of bleeding, chronic NSAIDs (including COX-2 inhibitors) and Efient should be co-administered with caution (see section 4.4).
Zaradi možnega povečanega tveganja za krvavitev, je pri sočasni uporabi NSAIDs (vključno z zaviralci COX-2) in zdravila Efient (glejte poglavje 4.4) potrebna previdnost.
Because of the potential for serious adverse reactions in breast-fed infants exposed to dexrazoxane, mothers must discontinue breast- feeding during Savene therapy (see section 4.3).
Zaradi potencialno resnih neželenih učinkov pri dojenih dojenčkih, ki so izpostavljeni deksrazoksanu, morajo matere prekiniti dojenje med zdravljenjem z zdravilom Savene (glejte poglavje 4.3).
Because of the potential for serious adverse reactions in breast-fed infants, a decision should be made whether to discontinue breast-feeding or Rebif therapy.
Zaradi potencialne nevarnosti resnih neželenih učinkov za dojence je treba sprejeti odločitev bodisi o prekinitvi dojenja ali pa prenehanju zdravljenja z zdravilom Rebif.
Because of the potential for serious adverse reactions in breast-fed infants, a decision should be made whether to discontinue breast-feeding or Rebif therapy.
Zaradi potencialne nevarnosti resnih neželenih učinkov za dojence, je treba sprejeti odločitev bodisi o prekinitvi dojenja ali pa prenehanju zdravljenja z zdravilom Rebif.
Because of the potential for serious adverse reactions in breast-feeding infants, a decision should be made either to discontinue breast-feeding or Plegridy therapy.
Zaradi možnosti resnih neželenih učinkov pri dojenih otrocih se je treba odločiti bodisi za prenehanje dojenja bodisi za prenehanje zdravljenja z zdravilom Plegridy.
Because of the potential for serious adverse reactions in infants, breastfeeding must be discontinued while taking Siklos.
Zaradi potencialno hudih neželenih učinkov pri dojenčkih, med jemanjem zdravila Siklos prenehajte z dojenjem.
Because of the potential for serious adverse reactions in nursing infants a decision should be made on whether to discontinue breast-feeding or discontinue Betaferon therapy.
Zaradi možnih resnih neželenih učinkov zdravila Betaferon pri dojenih otrocih se je treba odločiti bodisi za prenehanje dojenja bodisi za prenehanje zdravljenja z zdravilom Betaferon.
Because of the potential for serious adverse reactions in nursing infants a decision should be made whether to discontinue breast- feeding or Extavia therapy.
Zaradi možnosti resnih neželenih učinkov zdravila Extavia pri dojenih otrocih se je treba odločiti bodisi za prenehanje dojenja bodisi za prenehanje zdravljenja z zdravilom Extavia.
Because of the potential for serious adverse reactions in nursing infants from TRISENOX, breastfeeding must be discontinued prior to and throughout administration.
Zaradi morebitnih resnih neželenih učinkov zdravila TRISENOX pri dojenčkih morate dojenje prekiniti pred uporabo in med njo.
Because of the potential for serious adverse reactions in nursing infants, a decision should be made either to discontinue breast-feeding or AVONEX therapy.
Zaradi možnosti resnih neželenih učinkov pri dojenih otrocih se je treba odločiti za prekinitev dojenja ali zdravljenja z zdravilom AVONEX.
Because of the potential for serious adverse reactions of ONIVYDE in breast-feeding infants, ONIVYDE is contraindicated during breast-feeding (see section 4.3).
Zaradi možnosti resnih neželenih učinkov zdravila ONIVYDE pri dojenih otrocih je zdravilo ONIVYDE med dojenjem kontraindicirano (glejte poglavje 4.3).
Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, CellCept is contraindicated in nursing mothers (see section 4.3).
Zaradi možnih resnih škodljivih vplivov mofetilmikofenolata na dojenčke je zdravilo CellCept pri doječih materah kontraindicirano (glejte poglavje 4.3).
Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, Mycophenolate mofetil Teva is contraindicated in breast-feeding mothers (see section 4.3).
Zaradi možnih resnih škodljivih vplivov mofetilmikofenolata na dojenčke je zdravilo Mofetilmikofenolat Teva pri doječih materah kontraindicirano (glejte poglavje 4.3).
Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, Myfenax is contraindicated in breast-feeding mothers (see section 4.3).
Zaradi možnih resnih škodljivih vplivov mofetilmikofenolata na dojenčke je zdravilo Myfenax pri doječih materah kontraindicirano (glejte poglavje 4.3).
Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, Myfenax is contraindicated in breast-feeding mothers (see section 4.3).
Zaradi možnih resnih škodljivih vplivov mofetilmikofenolata na dojenčke, je zdravilo Myfenax pri doječih materah kontraindicirano (glejte poglavje 4.3).